Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

71%

5 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 4

3(60.0%)

Phase 3

2(40.0%)

5Total

Phase 4(3)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT00958633Phase 3Terminated

Mood Stabilizer (MS)+ Antidepressant vs MS + Placebo in Maintenance of Bipolar Disorder.

Role: collaborator

NCT04830215Phase 4Completed

Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder

Role: collaborator

NCT00401167Phase 4Completed

Memantine for Agitation and Aggression in Severe Alzheimer's Disease

Role: collaborator

NCT04907279Unknown

Aripiprazole Once-Monthly in Hospitalized Patients (INITIATE)

Role: collaborator

NCT02332954Phase 4Completed

Assessment in Work Productivity and the Relationship With Cognitive Symptoms in Patients With MDD Taking Vortioxetine

Role: lead

NCT01500083Phase 3Completed

Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia

Role: lead

NCT02131415Terminated

Real Life Assessment of Abilify Maintena

Role: lead

All 7 trials loaded